Lucid Diagnostics (LUCD)
(Delayed Data from NSDQ)
$0.86 USD
+0.02 (2.41%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $0.85 -0.01 (-1.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LUCD 0.86 +0.02(2.41%)
Will LUCD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LUCD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LUCD
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
LUCD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LUCD
Lucid Diagnostics Launches New Corporate Website
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuardĀ® Esophageal Precancer Testing in a Screening Population
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuardĀ® Esophageal Precancer Testing
Buy Rating Affirmed for Lucid Diagnostics Amidst Promising Products and Substantial Market Opportunity
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024